Hanyu Pharmaceutical: Expected to achieve operating revenue of 950 million to 980 million yuan and return to profitability with net profit attributable to parent company in 2025.

NightAirdropper · 2026-02-28T10:52:31+00:00

Hanyu Pharmaceutical revealed on the interactive platform on February 25th that by 2025, its operating revenue is expected to reach 950 million to 980 million yuan, with net profit attributable to the parent turning profitable, reaching 40 million to 50 million yuan. To seize opportunities in the GLP-1 market, the company is increasing its investment in R&D and international expansion.

NightAirdropper

2026-02-28 10:52:31

Abstract generation in progress

Securities Daily Network News: On February 25th, HanYu Pharmaceutical responded to investor questions on the interactive platform, stating that on January 28th, the company released its 2025 annual performance forecast, expecting total revenue of 950 million to 980 million yuan, and a return to profit with net profit attributable to shareholders turning positive, reaching 40 million to 50 million yuan. In the second half of 2025, to seize the rapid growth opportunity in the global GLP-1 market, the company proactively increased investment in R&D, capacity building, and international expansion, which are reflected in related expenses. However, the company’s main business continues to improve, and operating cash flow remains sufficient.

(Edited by Cong Kexin)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.